Polyenylphosphatidylcholine as bioactive excipient in tablets for the treatment of liver fibrosis
Ivo Skorup(University of Bern), Paola Luciani(University of Bern), Rita Gelli(University of Florence), Éric Felli(University of Bern), Jordi Gracia‐Sancho(Institut d'Investigacions Biomèdiques de Barcelona), Gina Valentino(University of Bern), Simone Aleandri(University of Bern), Annalisa Berzigotti(University of Bern), Sonia Selicean(University of Bern), Sarah Teworte(University of Bern), Aymar Abel Ganguin(University of Bern), Rosanne Angela Marxer(University of Bern), Francesca Ridi(University of Florence), Ana Lučić(University of Bern)
Cited by 4
Related Papers
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
|Journal of Hepatology|2020|163
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
|The Lancet. Gastroenterology & hepatology|2024|69
Genetic Ablation of SOX18 Function Suppresses Tumor Lymphangiogenesis and Metastasis of Melanoma in Mice
|Cancer Research|2012|67
Recent advances in fed-batch microscale bioreactor design
|Biotechnology Advances|2021|67